Latest News and Press Releases

Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Appoints Robert W. Duggan as Chief Executive Officer Oxford, UK, and Cambridge, MA, US, 14 April 2020 – Summit Therapeutics plc...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Appoints Robert W. Duggan as Executive Chairman Oxford, UK, and Cambridge, MA, US, 26 February 2020 – Summit Therapeutics plc (NASDAQ:...

Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) AIM Delisting Reminder Oxford, UK, and Cambridge, MA, US, 11 February 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader...

Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Notification of Transaction of Persons Discharging Managerial Responsibilities Oxford, UK, and Cambridge, MA, US, 10 February 2020 -...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma Milestone Based on Achievement of Patient Enrolment...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference Oxford, UK, and Cambridge, MA, US, 4 February 2020 – Summit...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Exercise of Restricted Stock Units Oxford, UK, and Cambridge, MA, US, 27 January 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Announces Management Update Oxford, UK, and Cambridge, MA, US, 24 January 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work Total Committed BARDA...